WHO Draft Guidance: Integration of Environmental Sustainability Strategies and Metrics into Pharmaceutical Manufacturing - For Comments
- Sharan Murugan
- 14 hours ago
- 3 min read
Environmental sustainability is becoming an essential consideration in pharmaceutical manufacturing as production activities consume significant amounts of energy, water, raw materials, and solvents while generating emissions, effluents, and waste. These activities can affect ecosystems, contribute to climate change, and influence long-term public health. To help manufacturers integrate sustainable practices into pharmaceutical operations, the World Health Organization (WHO) published the draft guidance Points to Consider on Integration of Environmental Sustainability Strategies and Metrics into Pharmaceutical Manufacturing.
The guidance provides practical recommendations for incorporating environmental sustainability principles and measurable performance indicators into pharmaceutical manufacturing while ensuring that product quality, patient safety, regulatory compliance, data integrity, and supply continuity are maintained. It promotes a practical, science-based, and risk-based approach that complements existing Good Manufacturing Practice (GMP) requirements.
Why Environmental Sustainability Matters
The guidance recognizes that while pharmaceutical manufacturing has traditionally focused on product quality, safety, and data integrity, environmental sustainability has not always been fully integrated into pharmaceutical quality systems. The guidance also aligns with internationally recognized environmental management frameworks and encourages manufacturers to adopt sustainable practices throughout the pharmaceutical product lifecycle.
Scope of the Guidance
The guidance applies to the manufacture and control of active pharmaceutical ingredients (APIs), excipients, and finished pharmaceutical products. It covers sustainability throughout pharmaceutical development, commercial manufacturing, quality control laboratories, facilities and utilities, packaging operations, and cleaning and waste management systems. It also introduces environmental performance indicators such as Process Mass Intensity (PMI), E-factor, energy use, water use, solvent recovery, and carbon footprint assessment to help organizations monitor and improve environmental performance.
Integrating Sustainability into Pharmaceutical Quality Systems
WHO recommends embedding environmental sustainability into existing pharmaceutical quality systems through documented policies, clearly defined responsibilities, measurable objectives, and effective governance. Senior management should lead sustainability initiatives while ensuring they remain aligned with GMP requirements.
The guidance also recommends applying quality risk management principles when implementing sustainability improvements. Environmental initiatives should be evaluated carefully to ensure they do not affect product quality, patient safety, process robustness, data integrity, or regulatory compliance.
Sustainable Manufacturing Operations
The guidance encourages manufacturers to optimize facilities, utilities, equipment, and manufacturing processes to reduce energy consumption, water usage, material losses, and waste generation while maintaining GMP compliance. HVAC systems, utilities, equipment performance, maintenance programmes, and cleaning operations should be regularly reviewed to identify opportunities for improving resource efficiency.
Environmental Sustainability in Quality Control Laboratories
WHO recommends adopting green analytical chemistry principles wherever scientifically appropriate while maintaining analytical performance and regulatory compliance. Laboratories are encouraged to reduce solvent consumption, use less hazardous reagents where feasible, optimize analytical methods, improve sample preparation techniques, and monitor resource consumption to identify opportunities for continual improvement.
Cleaning, Waste Management, Packaging and Distribution
The guidance recommends optimizing cleaning procedures to reduce water, solvent, and detergent consumption without affecting validated cleaning requirements or contamination control. Manufacturers should also establish effective waste management programmes that prioritize waste prevention, reduction, reuse, recycling, recovery, and responsible disposal.
Packaging and distribution activities should also support sustainability by reducing packaging materials, considering recyclable or renewable materials where appropriate, improving transportation efficiency, and reducing environmental impacts throughout the supply chain while maintaining product quality and stability.
Measuring Environmental Performance
A key focus of the guidance is the use of measurable environmental sustainability metrics to evaluate manufacturing performance and support continual improvement. Organizations are encouraged to establish standardized methods for monitoring indicators such as Process Mass Intensity (PMI), E-factor, energy consumption, water consumption, solvent recovery rate, carbon intensity, and greenhouse gas emissions.
Digital Technologies Supporting Sustainability
The guidance highlights the growing role of digital technologies in improving environmental performance. Digital monitoring systems, process analytical technologies, digital twins, life-cycle assessment tools, and artificial intelligence (AI) can help manufacturers optimize processes, monitor resource consumption, and improve environmental decision-making.
Training and Regulatory Considerations
Successful implementation of environmental sustainability requires both organizational commitment and employee awareness. The guidance recommends providing structured training on green chemistry, waste minimization, environmental management systems, sustainability reporting, and continuous improvement so that sustainability practices become part of routine pharmaceutical operations.
WHO is accepting comments on the guidance through its online platform, till 5th August, 2026.